Clinical Trial

A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single arm open-label phase 2 trial to study the safety and efficacy of SC Blinatumomab in combination with low-intensity chemotherapy for older or unfit patients with B-ALL.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-21
notable Enrollment reduced: 60 -> 3 participants 2026-05-21
Trial Details
NCT Number NCT07153796
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Amgen
Conditions B-cell Acute Lymphoblastic Leukemia
Enrollment 3 participants
Start Date 2026-01-30
Primary Completion 2031-09-30 (estimated)
Study Completion 2033-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-12